首页> 美国卫生研究院文献>BMC Cancer >A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors

【2h】

A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors

机译：PEP02（伊立替康脂质体注射液）与5-氟尿嘧啶和亚叶酸钙联合用于晚期实体瘤的I期剂量递增研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundPEP02 (also known as MM-398, nal-IRI) is a novel nanoparticle formulation of irinotecan encapsulated in liposomes. The aims of this study were to investigate the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of PEP02 in combination with 5-FU and LV, in patients with advanced refractory solid tumors.

机译：背景PEPO2（也称为MM-398，nal-IRI）是包裹在脂质体中的伊立替康的新型纳米颗粒制剂。这项研究的目的是研究PEP02与5-FU和LV联合用于晚期难治性实体瘤患者的剂量极限毒性（DLT），最大耐受剂量（MTD）和药代动力学（PK）。

著录项

期刊名称 BMC Cancer
作者
Nai-Jung Chiang; Tsu-Yi Chao; Ruey-Kuen Hsieh; Cheng-Hsu Wang; Yi-Wen Wang; C. Grace Yeh; Li-Tzong Chen;
展开▼
作者单位

展开▼
年(卷),期 2016(16),-1
年度 2016
页码 907
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Liposomal irinotecan 5-fluorouracil Dose-limiting toxicity Maximum tolerated dose;

机译：脂质体伊立替康;5-氟尿嘧啶;剂量限制性毒性;最大耐受剂量;

相似文献

外文文献
中文文献
专利

1. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors [J] . Nai-Jung Chiang, Tsu-Yi Chao, Ruey-Kuen Hsieh, BMC Cancer . 2016,第1期

机译：PEP02（伊立替康脂质体注射液）与5-氟尿嘧啶和亚叶酸钙联合用于晚期实体瘤的I期剂量递增研究
2. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours [J] . Eric Van Cutsem, David Khayat, Chris Verslype, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2013,第1期

机译：静脉注射AfliBercept与伊替康，5-氟尿嘧啶和白杨蛋白联合治疗晚期实体肿瘤
3. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors. [J] . Rachamalla R, Malamud S, Grossbard ML, Anti-cancer drugs . 2004,第3期

机译：在晚期胰腺癌或其他实体瘤患者中，每两周一次伊立替康联合固定剂量的5-氟尿嘧啶/亚叶酸钙，吉西他滨和顺铂（G-FLIP）的I期剂量研究。
4. Combination of 5-fluorouracil and low molecular weight hyaluronic acid improves efficiency of the targeting to tumors [C] . Z.K. Dong, Z.Y. Xu, Z.N. Yin The Second Asian symposium on pharmaceutical sciences and technology . 2011

机译：5-氟尿嘧啶和低分子量透明质酸的组合提高了靶向肿瘤的效率
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors [O] . Muhammad Wasif Saif, Sandra Sellers, Robert B. Diasio, -1

机译：Edotecarin（J-107088）的I次递增升级研究与晚期/转移性固体肿瘤患者的流管5-氟尿嘧啶和白草素相结合
7. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors [O] . 2016

机译：PEP02（伊立替康脂质体注射液）与5-氟尿嘧啶和亚叶酸钙联合用于晚期实体瘤的I期剂量递增研究

A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors

摘要

著录项

相似文献

相关主题

期刊订阅